neuroprotective agents

Summary

Summary: Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.

Top Publications

  1. ncbi 1,026 experimental treatments in acute stroke
    Victoria E O'Collins
    Neuroscience Lab, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, VIC 3084, Australia
    Ann Neurol 59:467-77. 2006
  2. ncbi Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease
    D C Wu
    Department of Neurology, Columbia University, New York, New York 10032, USA
    J Neurosci 22:1763-71. 2002
  3. ncbi Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention
    Bin Liu
    Neuropharmacology Section, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA
    J Pharmacol Exp Ther 304:1-7. 2003
  4. pmc ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease
    Pamela Maher
    Department of Cellular Neurobiology, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA
    Hum Mol Genet 20:261-70. 2011
  5. pmc Neuroprotection for ischemic stroke: past, present and future
    Myron D Ginsberg
    Department of Neurology D4 5, University of Miami Miller School of Medicine, Miami, FL 33101, USA
    Neuropharmacology 55:363-89. 2008
  6. ncbi Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult
    Andrew D Kraft
    School of Pharmacy, University of Wisconsin, Madison, Wisconsin 53705 2222, USA
    J Neurosci 24:1101-12. 2004
  7. pmc Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-β neurotoxicity
    Tetsuya Mizuno
    Department of Neuroimmunology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan
    Am J Pathol 179:2016-27. 2011
  8. pmc Neuroglobin protects the brain from experimental stroke in vivo
    Yunjuan Sun
    Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA
    Proc Natl Acad Sci U S A 100:3497-500. 2003
  9. pmc Heme oxygenase 1, beneficial role in permanent ischemic stroke and in Gingko biloba (EGb 761) neuroprotection
    Z A Shah
    Department of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH 43614, USA
    Neuroscience 180:248-55. 2011
  10. ncbi Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
    J G Nutt
    Oregon Health and Science University, Portland 97201 3098, USA
    Neurology 60:69-73. 2003

Research Grants

  1. INTERLEUKIN-1 AND PERINATAL BRAIN INJURY
    Faye Silverstein; Fiscal Year: 1999
  2. Non-Invasive Quantitation of Cellular and Biochemical Changes in Hereditary Ataxi
    GULIN OZ; Fiscal Year: 2009
  3. New York-Presbyterian NETT Consortium
    Stephan Mayer; Fiscal Year: 2009
  4. Treatment of acute stroke ethanol and caffeine
    James Grotta; Fiscal Year: 2002
  5. Molecular Interventions for Bipolar Disorder
    ALAN PAUL KOZIKOWSKI; Fiscal Year: 2010
  6. Molecular Interventions for Bipolar Disorder
    Alan Kozikowski; Fiscal Year: 2007
  7. Molecular Interventions for Bipolar Disorder
    Alan Kozikowski; Fiscal Year: 2009
  8. New York-Presbyterian NETT Consortium
    Stephan Mayer; Fiscal Year: 2007
  9. New York-Presbyterian NETT Consortium
    Stephan A Mayer; Fiscal Year: 2010
  10. Stem cell-mediated delivery of neurotrophic factors for treatment of glaucoma
    Donald S Sakaguchi; Fiscal Year: 2010

Detail Information

Publications374 found, 100 shown here

  1. ncbi 1,026 experimental treatments in acute stroke
    Victoria E O'Collins
    Neuroscience Lab, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, VIC 3084, Australia
    Ann Neurol 59:467-77. 2006
    ..Therefore, we endeavored to contrast experimental efficacy and scope of testing of drugs used clinically and those tested only experimentally...
  2. ncbi Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease
    D C Wu
    Department of Neurology, Columbia University, New York, New York 10032, USA
    J Neurosci 22:1763-71. 2002
    ..This study demonstrates that microglial-related inflammatory events play a significant role in the MPTP neurotoxic process and suggests that minocycline may be a valuable neuroprotective agent for the treatment of PD...
  3. ncbi Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention
    Bin Liu
    Neuropharmacology Section, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA
    J Pharmacol Exp Ther 304:1-7. 2003
    ..In addition, we also discuss novel approaches to potential therapeutic strategies...
  4. pmc ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease
    Pamela Maher
    Department of Cellular Neurobiology, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA
    Hum Mol Genet 20:261-70. 2011
    ..Thus, fisetin, resveratrol and related compounds might be useful for the treatment of HD by virtue of their unique ability to activate ERK...
  5. pmc Neuroprotection for ischemic stroke: past, present and future
    Myron D Ginsberg
    Department of Neurology D4 5, University of Miami Miller School of Medicine, Miami, FL 33101, USA
    Neuropharmacology 55:363-89. 2008
    ..This review presents a close survey of the most extensively evaluated neuroprotective agents and classes and considers both the strengths and weakness of the pre-clinical evidence as well as the ..
  6. ncbi Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult
    Andrew D Kraft
    School of Pharmacy, University of Wisconsin, Madison, Wisconsin 53705 2222, USA
    J Neurosci 24:1101-12. 2004
    ..Strikingly, the change in neuronal gene expression after tBHQ treatment was dependent on Nrf2 activity in the astrocytes. This suggests that Nrf2-dependent genetic changes alter neuron-glia interactions resulting in neuroprotection...
  7. pmc Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-β neurotoxicity
    Tetsuya Mizuno
    Department of Neuroimmunology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan
    Am J Pathol 179:2016-27. 2011
    ..These findings support the idea that enhancement of the neuroprotective property of microglia by IL-34 may be an effective approach against oAβ neurotoxicity in AD...
  8. pmc Neuroglobin protects the brain from experimental stroke in vivo
    Yunjuan Sun
    Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA
    Proc Natl Acad Sci U S A 100:3497-500. 2003
    ..We conclude that Ngb acts as an endogenous neuroprotective factor in focal cerebral ischemia and may therefore represent a target for the development of new treatments for stroke...
  9. pmc Heme oxygenase 1, beneficial role in permanent ischemic stroke and in Gingko biloba (EGb 761) neuroprotection
    Z A Shah
    Department of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH 43614, USA
    Neuroscience 180:248-55. 2011
    ..Together, these results suggest that HO1 plays, at least in part, an important role in the neuroprotective mechanism of EGb 761 and in delayed ischemia. Targeting this pathway could lead to neuroprotective agents against ischemic stroke.
  10. ncbi Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
    J G Nutt
    Oregon Health and Science University, Portland 97201 3098, USA
    Neurology 60:69-73. 2003
    ..To assess the safety, tolerability, and biological activity of glial cell line-derived neurotrophic factor (GDNF) administered by an implanted intracerebroventricular (ICV) catheter and access port in advanced PD...
  11. doi Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice
    Kavon Rezai-Zadeh
    Rashid Laboratory for Developmental Neurobiology, Silver Child Development Center, Department of Psychiatry and Behavioral Medicine, and Department of Neurosurgery, University of South Florida, Tampa, FL 33613, USA
    Brain Res 1214:177-87. 2008
    ..Taken together, these data further the notion of EGCG dietary supplementation as a potentially safe and effective prophylaxis for Alzheimer's disease...
  12. ncbi Use of anti-aging herbal medicine, Lycium barbarum, against aging-associated diseases. What do we know so far?
    Raymond Chuen Chung Chang
    Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
    Cell Mol Neurobiol 28:643-52. 2008
    ..barbarum. We hope that new findings for L. barbarum will pave a new avenue for the use of Chinese medicine in modern evidence-based medicine...
  13. ncbi Hydrogen sulfide protects neurons from oxidative stress
    Yuka Kimura
    National Institute of Neuroscience, Kodaira, Tokyo, Japan
    FASEB J 18:1165-7. 2004
    ..Cystine (cysteine) is the rate-limiting substrate of glutathione synthesis. These observations reveal that H2S protects neurons from oxytosis by increasing the production of the antioxidant glutathione...
  14. ncbi Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy
    Nadia Stefanova
    Clinical Neurobiology Unit, Neurodegeneration Research Laboratory, Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Mov Disord 22:2196-203. 2007
    ....
  15. ncbi Nutraceutical antioxidants as novel neuroprotective agents
    Natalie A Kelsey
    Department of Biological Sciences and Eleanor Roosevelt Institute, University of Denver, Denver, Colorado 80208, USA
    Molecules 15:7792-814. 2010
    ..Here, we review the literature pertaining to these various classes of nutraceutical antioxidants and discuss their potential therapeutic value in neurodegenerative diseases...
  16. ncbi Neuronal injury in rat model of permanent focal cerebral ischemia is associated with activation of autophagic and lysosomal pathways
    Ya Dan Wen
    Department of Pharmacology and Laboratory of Aging and Nervous Diseases, Soochow University School of Medicine, Suzhou, China
    Autophagy 4:762-9. 2008
    ..These results demonstrate that ischemic insult activates autophagy and an autophagic mechanism may contribute to ischemic neuronal injury. Thus, autophagy may be a potential target for developing a novel therapy for stroke...
  17. ncbi Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades
    M Digicaylioglu
    Center for Neuroscience and Aging Research, The Burnham Institute, La Jolla, CA 92037, USA
    Nature 412:641-7. 2001
    ..Thus neuronal EPORs activate a neuroprotective pathway that is distinct from previously well characterized Jak and NF-kappaB functions. Moreover, this EPO effect may underlie neuroprotection mediated by hypoxic-ischaemic preconditioning...
  18. ncbi Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia
    T M Tikka
    A. I. Virtanen Institute for Molecular Sciences, University of Kuopio, Kuopio, Finland
    J Immunol 166:7527-33. 2001
    ..Together, these results suggest that microglial activation contributes to NMDA excitotoxicity and that minocycline, a tetracycline derivative, represents a potential therapeutic agent for brain diseases...
  19. ncbi Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94
    M Asahi
    Department of Neurology, Massachusetts General Hospital, and Harvard Medical School, Charlestown 02129, USA
    J Cereb Blood Flow Metab 20:1681-9. 2000
    ..These data demonstrate that MMP-9 plays a deleterious role in the development of brain injury after focal ischemia...
  20. doi Peroxisome proliferator-activated receptor-α agonists protect cortical neurons from inflammatory mediators and improve peroxisomal function
    Elizabeth Gray
    University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, Bristol BS16 1JB, UK
    Eur J Neurosci 33:1421-32. 2011
    ....
  21. ncbi Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma
    Gustav Mattiasson
    Wallenberg Neuroscience Center, BMC A13, 221 84 Lund, Sweden
    Nat Med 9:1062-8. 2003
    ..We propose that UCP-2 is an inducible protein that is neuroprotective by activating cellular redox signaling or by inducing mild mitochondrial uncoupling that prevents the release of apoptogenic proteins...
  22. doi Lutein enhances survival and reduces neuronal damage in a mouse model of ischemic stroke
    Suk Yee Li
    Eye Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
    Neurobiol Dis 45:624-32. 2012
    ..The aim of this study is to investigate the protective roles of lutein in cerebral I/R injury...
  23. pmc TREK-1, a K+ channel involved in neuroprotection and general anesthesia
    C Heurteaux
    Institut de Pharmacologie Moleculaire et Cellulaire, CNRS, Institut Paul Hamel, Sophia Antipolis, Valbonne, France
    EMBO J 23:2684-95. 2004
    ..Trek1-/- mice are also resistant to anesthesia by volatile anesthetics. TREK-1 emerges as a potential innovative target for developing new therapeutic agents for neurology and anesthesiology...
  24. ncbi Neuroprotective effects of salidroside against beta-amyloid-induced oxidative stress in SH-SY5Y human neuroblastoma cells
    Li Zhang
    Jiangsu Institute of Nuclear Medicine, Key Laboratory of Nuclear Medicine, Ministry of Health, Wuxi, Jiangsu, China
    Neurochem Int 57:547-55. 2010
    ..These results suggest that salidroside has protective effects against Abeta(25-35)-induced oxidative stress, which might be a potential therapeutic agent for treating or preventing neurodegenerative diseases...
  25. doi Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury
    Emanuela Esposito
    Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, Italy
    Brain Behav Immun 25:1099-112. 2011
    ....
  26. ncbi Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection
    Merce Pallas
    Facultat de Farmacia, Institut de Biomedicina IBUB, Centro de Investigación de Biomedicina en Red de Enfermedades Neurodegenerativas, Universitat de Barcelona, Nucli Universitari de Pedralbes, Barcelona, Spain
    Curr Neurovasc Res 6:70-81. 2009
    ..In addition, we discuss the possibility of using resveratrol in the treatment of neurodegenerative diseases...
  27. pmc Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway
    D Della-Morte
    Cerebral Vascular Disease Research Center, Department of Neurology, Leonard M Miller School of Medicine, University of Miami, Miami, FL 33136, USA
    Neuroscience 159:993-1002. 2009
    ..In conclusion, in vivo resveratrol pretreatment confers neuroprotection similar to IPC via the SIRT1-UCP2 pathway...
  28. pmc Lycium barbarum polysaccharides reduce neuronal damage, blood-retinal barrier disruption and oxidative stress in retinal ischemia/reperfusion injury
    Suk Yee Li
    Eye Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
    PLoS ONE 6:e16380. 2011
    ..The present study suggests that LBP may have a neuroprotective role to play in ocular diseases for which I/R is a feature...
  29. doi Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials
    Maria Philip
    Department of Neurology, University of Texas Houston Medical School, Houston, TX 77030, USA
    Stroke 40:577-81. 2009
    Numerous neuroprotective agents have proven effective in animal stroke studies, but every drug has failed to achieve its primary outcome when brought forward to clinical trials...
  30. ncbi Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity
    A Bal-Price
    Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QW, United Kingdom
    J Neurosci 21:6480-91. 2001
    ..This may contribute to neuronal cell death in inflammatory, infectious, ischemic, and neurodegenerative diseases...
  31. ncbi Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases
    Orly Weinreb
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Technion Faculty of Medicine, 31096 Haifa, Israel
    J Nutr Biochem 15:506-16. 2004
    ..in well controlled epidemiological studies, aimed to alter brain aging processes and to serve as possible neuroprotective agents in progressive neurodegenerative disorders such as Parkinson's and Alzheimer's diseases...
  32. ncbi Nuclear Ca2+ and the cAMP response element-binding protein family mediate a late phase of activity-dependent neuroprotection
    Sofia Papadia
    Centre for Neuroscience Research, University of Edinburgh, Summerhall, Edinburgh EH9 1QH, United Kingdom
    J Neurosci 25:4279-87. 2005
    ..Thus, activity-dependent neuroprotection comprises two mechanistically distinct phases that differ in their spatial requirements for calcium and in their reliance on the CREB family...
  33. ncbi Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats
    Yi Zhao
    Institute of Pharmacology, University Hospital of Schleswig Holstein, Campus Kiel Hospitalstrasse 4 24105 Kiel, Germany
    FASEB J 20:1162-75. 2006
    ..Our data provide evidence that activation of neuronal PPARgamma considerably contributes to neuroprotection by prevention of COX-2 up-regulation in vitro and in peri-infarct brain areas...
  34. ncbi Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
    Jeffrey D Rothstein
    Department of Neurology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Nature 433:73-7. 2005
    ..Thus these studies provide a class of potential neurotherapeutics that act to modulate the expression of glutamate neurotransmitter transporters via gene activation...
  35. ncbi Leptin-mediated cell survival signaling in hippocampal neurons mediated by JAK STAT3 and mitochondrial stabilization
    Zhihong Guo
    Laboratory of Neurosciences and National Institute on Aging Intramural Research Program, Baltimore, MD 21224, USA
    J Biol Chem 283:1754-63. 2008
    ..By enhancing mitochondrial resistance to apoptosis and excitotoxicity, our findings suggest that leptin signaling serves a neurotrophic function in the developing and adult hippocampus...
  36. pmc Progesterone receptors: form and function in brain
    Roberta Diaz Brinton
    Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, School of Pharmacy, 1985 Zonal Avenue, Los Angeles, CA 90089, USA
    Front Neuroendocrinol 29:313-39. 2008
    ....
  37. ncbi Transforming growth factor-beta 1 increases bad phosphorylation and protects neurons against damage
    Yuan Zhu
    Institut für Pharmakologie und Toxikologie and Pharmazeutische Chemie, Philipps Universitat, D 35032 Marburg, Germany
    J Neurosci 22:3898-909. 2002
    ..Together, we demonstrate that TGF-beta1 suppresses Bad expression under lesion conditions, increases Bad phosphorylation, and activates the MAPK/Erk pathway, which may contribute to its neuroprotective activity...
  38. doi Involvement of ROS in BBB dysfunction
    Pamela B L Pun
    Defence Medical and Environmental Research Institute, DSO National Laboratories, Singapore
    Free Radic Res 43:348-64. 2009
    ..This review explores some of the pathways both upstream and downstream of ROS that have been implicated in increased BBB permeability and discusses the role of ROS and antioxidants in neuropathology...
  39. pmc Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury
    M L Brines
    The Kenneth S Warren Laboratories, 765 Old Saw Mill River Road, Tarrytown, NY 10591, USA
    Proc Natl Acad Sci U S A 97:10526-31. 2000
    ..Given r-Hu-EPO's excellent safety profile, clinical trials evaluating systemically administered r-Hu-EPO as a general neuroprotective treatment are warranted...
  40. pmc Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease
    Y Du
    Departmens of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Proc Natl Acad Sci U S A 98:14669-74. 2001
    ..Thus, NO appears to play an important role in MPTP neurotoxicity. Neuroprotective tetracyclines may be effective in preventing or slowing the progression of Parkinson's and other neurodegenerative diseases...
  41. ncbi Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration
    Toshiyuki Araki
    Department of Pathology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Science 305:1010-3. 2004
    ..These findings suggest that novel therapeutic strategies directed at increasing the supply of NAD and/or Sir2 activation may be effective for treatment of diseases characterized by axonopathy and neurodegeneration...
  42. pmc Neuroprotective effects of curcumin
    Greg M Cole
    Greater Los Angeles Veterans Affairs Healthcare System, Geriatric Research, Education, and Clinic Center, Sepulveda, CA 91343, USA
    Adv Exp Med Biol 595:197-212. 2007
    ..Promising results have already led to ongoing pilot clinical trials...
  43. ncbi Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy
    E Carro
    Laboratory of Neuroendocrinology, Cajal Institute, Consejo Superior de Investigaciones Cientificas, 28002 Madrid, Spain
    J Neurosci 21:5678-84. 2001
    ..These findings also support the use of IGF-I as a therapeutical aid in brain diseases coursing with either acute or progressive neuronal death...
  44. ncbi Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice
    Jennifer E A Wells
    University of Calgary, 3330 Hospital Drive, Calgary, Alberta, Canada T2N 4N1
    Brain 126:1628-37. 2003
    ..Finally, a comparison of minocycline against the currently approved treatment for acute SCI in humans, methylprednisolone, demonstrated superior behavioural recovery in the minocycline-treated animals...
  45. ncbi Increases in β-amyloid protein in the hippocampus caused by diabetic metabolic disorder are blocked by minocycline through inhibition of NF-κB pathway activation
    Zhiyou Cai
    Department of Neurology, Affiliated Hospital, Guangdong Medical College, Zhanjiang, China
    Pharmacol Rep 63:381-91. 2011
    ..In sum, diabetes contributes to the activation of the NF-κB pathway and upregulates BACE1 and Aβ. Minocycline downregulates Aβ in the hippocampus by inhibiting NF-κB pathway activation...
  46. ncbi CORM-3, a carbon monoxide-releasing molecule, alters the inflammatory response and reduces brain damage in a rat model of hemorrhagic stroke
    Andriy Yabluchanskiy
    Department of Surgical Research, Northwick Park Institute for Medical Research, Harrow, Middlesex, UK
    Crit Care Med 40:544-52. 2012
    ..We assessed the effect of CORM-3, a water-soluble carbon monoxide-releasing molecule possessing anti-inflammatory properties, on inflammation and brain injury after intracerebral hemorrhage...
  47. pmc Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease
    Xin Wang
    Neuroapoptosis Laboratory, Department of Neurosurgery, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:10483-7. 2003
    ..Our results further delineate the mechanism by which minocycline mediates its remarkably broad neuroprotective effects...
  48. ncbi Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents
    Ravinder K Kaundal
    Department of Pharmacology and Toxicology of the National Institute of Pharmaceutical Education and Research NIPER, Mohali, Punjab, India
    Drug News Perspect 23:241-56. 2010
    ..This article discusses evidence and mechanisms supporting the neuroprotective effects of PPARgamma agonists in central nervous system disorders...
  49. ncbi STAT3 activation in photoreceptors by leukemia inhibitory factor is associated with protection from light damage
    Yumi Ueki
    Oklahoma Center for Neuroscience, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
    J Neurochem 105:784-96. 2008
    ..Our data suggest that photoreceptor protection in response to LIF can be directly mediated by activation of STAT3 in photoreceptors...
  50. doi Neuroinflammation: modulation by flavonoids and mechanisms of action
    Jeremy P E Spencer
    Molecular Nutrition Group, Centre for Integrative Neuroscience and Neurodynamics, School of Chemistry, Food and Pharmacy, University of Reading, Reading RG6 6AP, UK
    Mol Aspects Med 33:83-97. 2012
    ..As such, flavonoids represent important precursor molecules in the quest to develop of a new generation of drugs capable of counteracting neuroinflammation and neurodegenerative disease...
  51. doi Emodin-induced microglial apoptosis is associated with TRB3 induction
    Xueping Zhou
    the Clinical Research Institute, First College of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China
    Immunopharmacol Immunotoxicol 33:594-602. 2011
    ..Our findings provide a novel molecular basis through which emodin exerts neuroprotective effects, treating brain injury after intracerebral hemorrhage...
  52. doi The role of ASIC1a in neuroprotection elicited by quercetin in focal cerebral ischemia
    Anand Kumar Pandey
    Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Brig SK Mazumdar Road, Delhi 110054, India
    Brain Res 1383:289-99. 2011
    ..These studies suggest the neuroprotective role of quercetin in focal cerebral ischemia by regulation of ASIC1a...
  53. ncbi Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action
    Hyeon Ju Kim
    Molecular Neurobiology Section, National Institute of Mental Health, National Institutes of Health, Building 10, Bethesda, MD 20892 1363, USA
    J Pharmacol Exp Ther 321:892-901. 2007
    ..Given that there is no effective treatment for stroke, HDAC inhibitors, such as VPA, SB, and TSA, should be evaluated for their potential use for clinical trials in stroke patients...
  54. ncbi Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons
    Hui Ming Gao
    Neuropharmacology Section, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences National Institutes of Health, Research Triangle Park, North Carolina 27709, USA
    J Neurosci 23:6181-7. 2003
    ..This study also suggested that microglial NADPH oxidase may be a promising target for PD treatment...
  55. ncbi Insights into the putative catechin and epicatechin transport across blood-brain barrier
    Ana Faria
    Department of Biochemistry U38 FCT, Faculty of Medicine, University of Porto, Al Prof Hernani Monteiro, 4200 319 Porto, Portugal
    Food Funct 2:39-44. 2011
    ..Nevertheless, the information obtained by this study is valuable for the new insights about flavan-3-ols transport...
  56. ncbi Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia
    T Tikka
    A. I. Virtanen Institute for Molecular Sciences, University of Kuopio, FIN-70211 Kuopio, Finland
    J Neurosci 21:2580-8. 2001
    ..These findings indicate that the proliferation and activation of microglia contributes to excitotoxicity, which is inhibited by minocycline, an antibiotic used in severe human infections...
  57. doi Curcumin improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats
    Jing Zhao
    Department of Pathophysiology, Molecular Medicine and Tumor Center, Chongqing Medical University, Chongqing, China
    Neurochem Res 35:374-9. 2010
    ..Inhibition of oxidative stress with curcumin treatment improves outcomes after focal cerebral ischemia. This neuroprotective effect is likely exerted by antiapoptotic mechanisms...
  58. ncbi ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury
    David W Wright
    Department of Emergency Medicine, School of Medicine of Emory University, Atlanta, GA, USA
    Ann Emerg Med 49:391-402, 402.e1-2. 2007
    ..Laboratory evidence indicates that progesterone has potent neuroprotective effects. We conducted a pilot clinical trial to assess the safety and potential benefit of administering progesterone to patients with acute traumatic brain injury...
  59. doi Polysaccharides from wolfberry antagonizes glutamate excitotoxicity in rat cortical neurons
    Yuen Shan Ho
    Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China
    Cell Mol Neurobiol 29:1233-44. 2009
    ..Taken together, LBA exerted significant neuroprotective effects on cultured cortical neurons exposed to glutamate...
  60. doi ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD
    Jianfeng Shen
    Laboratory of Clinical Visual Sciences, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, Shanghai, China
    Invest Ophthalmol Vis Sci 51:35-46. 2010
    ..To characterize the neuroprotective mechanisms of erythropoietin (EPO) against the stress of glyoxal-advanced glycation end products (AGEs) in retinal neuronal cells...
  61. ncbi Neuroprotective effects of leptin against ischemic injury induced by oxygen-glucose deprivation and transient cerebral ischemia
    Feng Zhang
    Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Stroke 38:2329-36. 2007
    ..Leptin receptors are also present in other cell types, and a potent antiapoptotic effect for leptin has recently been reported. We investigated whether leptin was neuroprotective against ischemic brain injury...
  62. pmc Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia
    Xiurong Zhao
    Stroke Program, Department of Neurology, University of Texas, Houston, Medical School, Houston, Texas 77030, USA
    J Neurosci 29:6186-95. 2009
    ..Therefore, we conclude that PPARgamma in neurons play an essential protective function and that PPARgamma agonists may have utility in neuronal self-defense, in addition to their well established anti-inflammatory effect...
  63. ncbi Characterization of the effects of anti-aging medicine Fructus lycii on beta-amyloid peptide neurotoxicity
    Man Shan Yu
    Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, P R China
    Int J Mol Med 20:261-8. 2007
    ..As herbal medicine has received increasing attention for the treatment of AD, our study will open a window for the development of a neuroprotective agent for anti-aging from Chinese medicine...
  64. ncbi Neuroprotective effects of salidroside in the PC12 cell model exposed to hypoglycemia and serum limitation
    Shu Yu
    Jiangsu Key Laboratory of Neuroregeneration, Nantong University, Nantong, JS 226001, People s Republic of China
    Cell Mol Neurobiol 28:1067-78. 2008
    ..Our findings might raise a possibility of potential therapeutic applications of salidroside for preventing and treating cerebral ischemic and neurodegenerative diseases...
  65. doi Tripchlorolide protects neuronal cells from microglia-mediated beta-amyloid neurotoxicity through inhibiting NF-kappaB and JNK signaling
    Xiao Dong Pan
    Department of Neurology, Union Hospital of Fujian Medical University, Fuzhou, Fujian, People s Republic of China
    Glia 57:1227-38. 2009
    ..Therefore, T4 may be an effective agent in modulating neuroinflammatory process in AD...
  66. ncbi Minocycline delays disease onset and mortality in a transgenic model of ALS
    Ludo Van Den Bosch
    Laboratory for Neurobiology, Campus Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Neuroreport 13:1067-70. 2002
    ..These results demonstrate that interference with immuno-inflammatory responses has a beneficial effect in the ALS mice model, suggesting this to be a potential new strategy to treat ALS...
  67. ncbi The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice
    H Mayumi Homi
    Department of Anesthesiology Multidisciplinary Neuroprotection Laboratories, Duke University Medical Center, Durham, North Carolina, USA
    Anesthesiology 99:876-81. 2003
    ..However, its putative neuroprotective properties have not been evaluated in focal cerebral ischemia. The purpose of this study was to determine if xenon offers neuroprotection in a mouse model of middle cerebral artery occlusion...
  68. ncbi Neuroprotective effects of Lycium barbarum Lynn on protecting retinal ganglion cells in an ocular hypertension model of glaucoma
    Hiu Chi Chan
    Department of Anatomy, Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR
    Exp Neurol 203:269-73. 2007
    ..barbarum against neurodegeneration in the retina of rat OH model. The results demonstrate that this extract may be a potential candidate for the development of neuroprotective drug against the loss of RGCs in glaucoma...
  69. ncbi Edaravone prevents kainic acid-induced neuronal death
    Ryohei Miyamoto
    Department of Pediatrics, Osaka Medical College, Japan
    Brain Res 1209:85-91. 2008
    ..Patients who develop status epilepticus are unlikely to receive adequate antioxidant therapy before the onset, so it is an advantage that Ed can prevent neuronal death even when administered after seizures...
  70. ncbi Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate
    Pamela L Follett
    Department of Neurology and Program in Neuroscience, Children s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 24:4412-20. 2004
    ....
  71. ncbi Neuroprotection in traumatic brain injury: a complex struggle against the biology of nature
    Joost W Schouten
    Department of Neurosurgery, Erasmus Medical Center, Rotterdam, The Netherlands
    Curr Opin Crit Care 13:134-42. 2007
    Translating the efficacy of neuroprotective agents in experimental traumatic brain injury to clinical benefit has proven an extremely complex and, to date, unsuccessful undertaking...
  72. doi Preconditioning and postinsult therapies for perinatal hypoxic-ischemic injury at term
    Robert D Sanders
    Departments of Anaesthetics, Medical Research Council Clinical Sciences Centre, Queen Charlotte s and Chelsea Hospital, Imperial College London, London, United Kingdom
    Anesthesiology 113:233-49. 2010
    ..Advances in the understanding of preconditioning may lead to the administration of neuroprotective agents earlier during childbirth...
  73. ncbi Minocycline treatment in acute stroke: an open-label, evaluator-blinded study
    Y Lampl
    Department of Neurology, Edith Wolfson Medical Center, Holon 58100, Israel
    Neurology 69:1404-10. 2007
    ..Ischemic animal model studies have shown a neuroprotective effect of minocycline...
  74. doi A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?
    Mark C Bellingham
    School of Biomedical Sciences, University of Queensland, Brisbane, QLD 4072, Australia
    CNS Neurosci Ther 17:4-31. 2011
    ..This effect may have implications for the management of hypoventilation and sleep-disordered breathing during end-stage ALS in humans...
  75. doi p120 catenin/αN-catenin are molecular targets in the neuroprotection and neuronal plasticity mediated by atorvastatin after focal cerebral ischemia
    Angel Céspedes-Rubio
    Neuroscience Group, Cellular and Molecular Neurobiology Area, School of Medicine, SIU, Universidad de Antioquia, Medellin, Colombia
    J Neurosci Res 88:3621-34. 2010
    ..Our findings suggested that p120(ctn) and αN-catenin synaptic adhesion proteins are crucial molecular targets in ATV-mediated neuroprotection and neuronal plasticity after focal cerebral ischemia...
  76. doi Cyclosporine A attenuates hypoxic-ischemic brain injury in newborn rats
    Jong Hee Hwang
    Department of Pediatrics, Ilsan Paik Hospital, College of Medicine, Inje University, Ilsan, Republic of Korea
    Brain Res 1359:208-15. 2010
    ....
  77. doi Neuroprotection in glaucoma: recent and future directions
    Helen V Danesh-Meyer
    Department of Ophthalmology, University of Auckland, Auckland, New Zealand
    Curr Opin Ophthalmol 22:78-86. 2011
    ..This review focuses on strategies for neuroprotection and summarizes preclinical studies that have investigated potential agents over the last 2 years...
  78. doi Neuroprotective effects of Salidroside and its analogue tyrosol galactoside against focal cerebral ischemia in vivo and H2O2-induced neurotoxicity in vitro
    Tian Yao Shi
    Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi an 710032, China
    Neurotox Res 21:358-67. 2012
    ..This gives a new insight into the development of therapeutic natural antioxidants against oxidative stress...
  79. doi Xenon preconditioning confers neuroprotection regardless of gender in a mouse model of transient middle cerebral artery occlusion
    V Limatola
    Department of Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, Chelsea and Westminster Hospital, London, UK
    Neuroscience 165:874-81. 2010
    ..HIF-1alpha and phospho-Akt were quantitatively upregulated in both sexes. Our data suggested that xenon preconditioning improved histological and neurological functional outcome in both gender in a stroke model of mice...
  80. pmc Neuronal estrogen receptor-alpha mediates neuroprotection by 17beta-estradiol
    Joachim G Elzer
    Division of Molecular Biology of the Cell 1, German Cancer Research Center, Heidelberg, Germany
    J Cereb Blood Flow Metab 30:935-42. 2010
    ..We conclude that neuronal ER alpha in female and male mice mediates neuroprotective estrogen effects in an in vivo mouse model of stroke, whereas microglial ER alpha is dispensable...
  81. ncbi Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
    P Klivenyi
    Neurochemistry Laboratory, Neurology Service, Massachusetts General Hospital and Harvard Medical School, Boston 02118, USA
    Nat Med 5:347-50. 1999
    ..Creatine administration protected G93A transgenic mice from increases in biochemical indices of oxidative damage. Therefore, creatine administration may be a new therapeutic strategy for ALS...
  82. pmc Erythropoietin improves histological and functional outcomes after traumatic brain injury in mice in the absence of the neural erythropoietin receptor
    Ye Xiong
    Department of Neurosurgery, Henry Ford Health System, Detroit, Michigan 48202, USA
    J Neurotrauma 27:205-15. 2010
    ..These data demonstrate that EPO significantly provides neuroprotection following TBI, even in the absence of EPOR in the neural cells, suggesting that its therapeutic benefits may be mediated through vascular protection...
  83. ncbi Neuroprotective effect of Bax-inhibiting peptide on neonatal brain injury
    Xiaoyang Wang
    Department of Physiology, Perinatal Center, Sahlgrenska Academy, University of Gothenburg, Box 432, S 405 30 Gothenburg, Sweden
    Stroke 41:2050-5. 2010
    ..The aim of this study was to evaluate the neuroprotective effect of a cell-penetrating Bax-inhibiting peptide (BIP) on neonatal mouse HI brain injury...
  84. pmc Reproductive age modulates the impact of focal ischemia on the forebrain as well as the effects of estrogen treatment in female rats
    Amutha Selvamani
    Department of Neuroscience and Experimental Therapeutics, Texas A and M Health Science Center, College Station, TX 77843 1114, USA
    Neurobiol Aging 31:1618-28. 2010
    ....
  85. doi Tetrahydrocurcumin confers protection against amyloid β-induced toxicity
    Shilpa Mishra
    National Brain Research Centre, Manesar, Haryana, India
    Neuroreport 22:23-7. 2011
    ..Thus, THC confers protection against amyloid-β-induced toxicity, and the antioxidant activity may contribute to its protective effect...
  86. ncbi Modulation of the endocannabinoid system: neuroprotection or neurotoxicity?
    Christopher J Fowler
    Department of Pharmacology and Clinical Neuroscience, Umea University, SE 901 87 Umea, Sweden
    Exp Neurol 224:37-47. 2010
    ....
  87. ncbi Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders
    Makoto Naoi
    Department of Neurosciences, Gifu International Institute of Biotechnology, 1 1 Nakafudogaoka, Kakamigahara, Gifu 504 0838, Japan
    Curr Pharm Des 16:2799-817. 2010
    ..the inhibitors of type B monoamine oxidase, such as selegiline and rasagiline, are the most promising neuroprotective agents to date. These inhibitors protect neuronal cells against cell death induced in cellular and animal models...
  88. ncbi Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress
    Nicolas G Bazan
    LSU Neuroscience Center and Department of Opthamology, Louisiana State University Health Sciences Center School of Medicine, New Orleans 70112, USA
    Brain Pathol 15:159-66. 2005
    ....
  89. ncbi Neuroprotective effects of female gonadal steroids in reproductively senescent female rats
    N J Alkayed
    Department of Anesthesiology, Division of Comparative Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Stroke 31:161-8. 2000
    ....
  90. pmc Neuroprotection in the newborn infant
    Fernando F Gonzalez
    Department of Pediatrics, University of California, 521 Parnassus Avenue, C215, Box 0663, San Francisco, CA 94143, USA
    Clin Perinatol 36:859-80, vii. 2009
    ..More recent evidence suggests combined therapy may optimize repair, decreasing cell injury while increasing newly born cells...
  91. doi Neuroprotection by baicalein in ischemic brain injury involves PTEN/AKT pathway
    Chao Liu
    Department of Pharmacology, Pharmaceutical College, Xianning University, Xianning, China
    J Neurochem 112:1500-12. 2010
    ..Together, these findings provide evidence that Bai protects neurons against ischemia injury and this neuroprotective effect involves PI3K/Akt and PTEN pathway...
  92. ncbi Targeting the p53 pathway to protect the neonatal ischemic brain
    Cora H Nijboer
    Laboratory of Neuroimmunology and Developmental Origins of Disease, University Medical Center Utrecht, Utrecht, The Netherlands
    Ann Neurol 70:255-64. 2011
    ..To investigate whether inhibition of mitochondrial p53 association using pifithrin-μ (PFT-μ) represents a potential novel neuroprotective strategy to combat perinatal hypoxic-ischemic (HI) brain damage...
  93. pmc Neuroprotective strategies involving ROS in Alzheimer disease
    Magali Dumont
    Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, NY 10065, USA
    Free Radic Biol Med 51:1014-26. 2011
    ..Nonetheless, there is still hope for improved compounds that would better target pathways implicated in ROS production. In fact, facilitating the endogenous antioxidant system by modulating transcription has great promise for AD therapy...
  94. ncbi Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners
    Keith A Wollen
    Psychology Department of Washington State University, USA
    Altern Med Rev 15:223-44. 2010
    ..Approaches that target several dysfunctions simultaneously and that emphasize nutritional, botanical, and stimulatory therapies may offer the most benefit at this time...
  95. doi Actions of estrogens on glial cells: Implications for neuroprotection
    Maria Angeles Arevalo
    Instituto Cajal, CSIC, Madrid, Spain
    Biochim Biophys Acta 1800:1106-12. 2010
    ..Therefore, glial cells are important players in the neuroprotective and reparative mechanisms of estrogenic compounds...
  96. doi Inhibition of extracellular signal-regulated kinases 1/2 provides neuroprotection in spinal cord ischemia/reperfusion injury in rats: relationship with the nuclear factor-kappaB-regulated anti-apoptotic mechanisms
    Kang Lu
    Department of Neurosurgery, E Da Hospital, I Shou University, Kaohsiung 824, Taiwan
    J Neurochem 114:237-46. 2010
    ..Future research should focus on the possible cross-talk between the MEK/ERK pathway and the NF-kappaB transcriptional cascade...
  97. ncbi Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association
    Majid Fotuhi
    Center for Memory and Brain Health, LifeBridge Health Brain and Spine Institute, Sinai Hospital of Baltimore, Baltimore, MD 21209, USA
    Nat Clin Pract Neurol 5:140-52. 2009
    ..Large clinical trials of extended duration should help to provide definitive answers...
  98. ncbi Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways
    R D Almeida
    Center for Neuroscience and Cell Biology and Department of Zoology, University of Coimbra, 3004 517 Coimbra, Portugal
    Cell Death Differ 12:1329-43. 2005
    ..The results indicate that the protective effect of BDNF in hippocampal neurons against glutamate toxicity is mediated by the PI3-K and the Ras/MAPK signaling pathways, and involves a long-term change in protein synthesis...
  99. pmc Neurotrophin roles in retinal ganglion cell survival: lessons from rat glaucoma models
    Elaine C Johnson
    The Kenneth C Swan Ocular Neurobiology Laboratory, Casey Eye Institute, Ceres, Oregon Health and Science University, Portland, OR 97239, USA
    Exp Eye Res 88:808-15. 2009
    ..The examination of these studies in this review reveals a number of consistent observations and provides direction for further investigations of this hypothesis...
  100. pmc Sex differences in minocycline-induced neuroprotection after experimental stroke
    Jun Li
    Department of Neurology, University of Connecticut Health Center, Farmington, Connecticut 06030, USA
    J Cereb Blood Flow Metab 29:670-4. 2009
    ..Clinical trials must consider possible sex differences in the response to neuroprotective agents, if we hope to translate promising therapies to stroke patients of both sexes.
  101. doi Neuropharmacological and pharmacokinetic properties of berberine: a review of recent research
    Minzhong Ye
    Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Sun Yat Sen University, Guangzhou, PR China
    J Pharm Pharmacol 61:831-7. 2009
    ..This review summarizes recent research on the neuropharmacological and pharmacokinetic properties of berberine, an isoquinoline alkaloid extracted from Coptidis rhizoma...

Research Grants88

  1. INTERLEUKIN-1 AND PERINATAL BRAIN INJURY
    Faye Silverstein; Fiscal Year: 1999
    ..of observed effects are to be assessed, as well as effects produced when IL-1ra is combined with other neuroprotective agents such as MK-801...
  2. Non-Invasive Quantitation of Cellular and Biochemical Changes in Hereditary Ataxi
    GULIN OZ; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Successful application of potential neuroprotective agents will depend on early detection of neurodegenerative diseases...
  3. New York-Presbyterian NETT Consortium
    Stephan Mayer; Fiscal Year: 2009
    ..ischemic stroke, midazolam infusion for refractory status epilepticus, and clinical trials evaluating neuroprotective agents for acute stroke, thrombolytic therapy for intraventricular hemorrhage, and ultra-early hemostatic therapy ..
  4. Treatment of acute stroke ethanol and caffeine
    James Grotta; Fiscal Year: 2002
    ..It is unclear if these doses will be tolerated or effective in human stroke patients. However, the doses to be used in this study are well within the usually consumed amounts of these compounds. ..
  5. Molecular Interventions for Bipolar Disorder
    ALAN PAUL KOZIKOWSKI; Fiscal Year: 2010
    ..the pro-apoptotic properties of the GSK-3 enzyme suggest a potential use of such inhibitors as neuroprotective agents. Neuroprotection may further contribute to the therapeutic efficacy of mood disorder drugs...
  6. Molecular Interventions for Bipolar Disorder
    Alan Kozikowski; Fiscal Year: 2007
    ..the pro-apoptotic properties of the GSK-3 enzyme suggest a potential use of such inhibitors as neuroprotective agents. Neuroprotection may further contribute to the therapeutic efficacy of mood disorder drugs...
  7. Molecular Interventions for Bipolar Disorder
    Alan Kozikowski; Fiscal Year: 2009
    ..the pro-apoptotic properties of the GSK-3 enzyme suggest a potential use of such inhibitors as neuroprotective agents. Neuroprotection may further contribute to the therapeutic efficacy of mood disorder drugs...
  8. New York-Presbyterian NETT Consortium
    Stephan Mayer; Fiscal Year: 2007
    ..ischemic stroke, midazolam infusion for refractory status epilepticus, and clinical trials evaluating neuroprotective agents for acute stroke, thrombolytic therapy for intraventricular hemorrhage, and ultra-early hemostatic therapy ..
  9. New York-Presbyterian NETT Consortium
    Stephan A Mayer; Fiscal Year: 2010
    ..ischemic stroke, midazolam infusion for refractory status epilepticus, and clinical trials evaluating neuroprotective agents for acute stroke, thrombolytic therapy for intraventricular hemorrhage, and ultra-early hemostatic therapy ..
  10. Stem cell-mediated delivery of neurotrophic factors for treatment of glaucoma
    Donald S Sakaguchi; Fiscal Year: 2010
    ..is that transplanted, genetically modified bone marrow-derived stem cells can be used as effective neuroprotective agents to mediate preservation and rescue of visual function in the rat model of experimental glaucoma...
  11. Stem cell-mediated delivery of neurotrophic factors for treatment of glaucoma
    DONALD SAKAGUCHI; Fiscal Year: 2009
    ..is that transplanted, genetically modified bone marrow-derived stem cells can be used as effective neuroprotective agents to mediate preservation and rescue of visual function in the rat model of experimental glaucoma...
  12. Novel Mitochondrial Targeted Neuroprotectants for Glaucoma
    Leonard Levin; Fiscal Year: 2009
    ....
  13. Novel Mitochondrial Targeted Neuroprotectants for Glaucoma
    Leonard Levin; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  14. Neuroprotective Drugs for Spinal Cord Injury
    JEAN WRATHALL; Fiscal Year: 2001
    ..Ionotropic glutamate antagonists, administered acutely after injury showed promise as neuroprotective agents which has not been borne out by clinical trials due to adverse side effects...
  15. Thrombin Mediated Cytotoxicity during Cerebral Ischemia
    Patrick D Lyden; Fiscal Year: 2011
    ..The proposal will enable us to confirm and extend our promising preliminary findings as well as help us understand how thrombin contributes to brain injury after stroke. ..
  16. Estrogen-neuroprotection due to astroglial Glu transporters occurs via TGF-a/b1
    EUN SOOK YU LEE; Fiscal Year: 2010
    ..Moreover, we will also test whether growth factors, TGF-1/2, mediate E2/TX-induced restoration of glutamate transporters. ..
  17. Broadly Neuroprotective Drug for TBI
    Fernando Gomez Pinilla; Fiscal Year: 2010
    ..We expect to generate valuable pre-clinical information that will entitle us to initiate the steps for seeking IND approval. ..
  18. Broadly Neuroprotective Drug for TBI
    Fernando Gomez Pinilla; Fiscal Year: 2009
    ..We expect to generate valuable pre-clinical information that will entitle us to initiate the steps for seeking IND approval. ..
  19. Protection of Brain Injury from Cyanide Poisoning by Carnosic Acid
    Stuart A Lipton; Fiscal Year: 2012
    ..Here, we propose to use carnosic acid, a pro-electrophilic compound found in the herb rosemary, to prevent brain injury from cyanide subchronic poisoning. ..
  20. Protection of Mice From Lethal Alphavirus Encephalitis
    David Irani; Fiscal Year: 2006
    ....
  21. Protection of Mice From Lethal Alphavirus Encephalitis
    David Irani; Fiscal Year: 2007
    ....
  22. Protection of Mice From Lethal Alphavirus Encephalitis
    David Irani; Fiscal Year: 2009
    ....
  23. Progesterone /Melatonin as Neuroprotectants in Nerve Inj
    WAN HUA YU; Fiscal Year: 2003
    ..abstract_text> ..
  24. Cerebal Ischemia During Anesthesia and Surgery
    Piyush Patel; Fiscal Year: 2004
    ..Anesthetics are logical candidate neuroprotective agents because they reduce excitotoxic injury...
  25. Cerebal Ischemia During Anesthesia and Surgery
    Piyush Patel; Fiscal Year: 2001
    ..Anesthetics are logical candidate neuroprotective agents because they reduce excitotoxic injury...
  26. Cerebal Ischemia During Anesthesia and Surgery
    Piyush Patel; Fiscal Year: 2002
    ..Anesthetics are logical candidate neuroprotective agents because they reduce excitotoxic injury...
  27. UCLA SPOTRIAS CENTER APPLICATION RENEWAL-PROGRAM PROJECT
    Jeffrey Saver; Fiscal Year: 2009
    ..This trial will be the first formal study of endovascular infusion of neuroprotective agents, a highly promising complementary strategy to endovascular recanalization...
  28. Cerebal Ischemia During Anesthesia and Surgery
    Piyush Patel; Fiscal Year: 2003
    ..Anesthetics are logical candidate neuroprotective agents because they reduce excitotoxic injury...
  29. UCLA SPOTRIAS CENTER APPLICATION RENEWAL-PROGRAM PROJECT
    Jeffrey L Saver; Fiscal Year: 2010
    ..This trial will be the first formal study of endovascular infusion of neuroprotective agents, a highly promising complementary strategy to endovascular recanalization...
  30. Neuroprotection by Mitochondria-targeted Antioxidants
    Balaraman Kalyanaraman; Fiscal Year: 2009
    ....
  31. OXYGEN RADICAL TOXICITY AND CHRONIC NEURONAL LOSS
    Jeffrey Rothstein; Fiscal Year: 1999
    ..If this were true it would have fundamental consequences for our understanding on chronic oxidative insults in neural degenerative disorders and aging, and how to approach them neuropharmacologically. ..
  32. Parkinson's Disease Neuroprotection Clinical Center
    Charles Adler; Fiscal Year: 2003
    ..To this end creating a multi-center study group to run clinical trials of potential neuroprotective agents has been set as a goal of the NIH...
  33. Parkinson's Disease Neuroprotection Clinical Center
    Charles Adler; Fiscal Year: 2002
    ..To this end creating a multi-center study group to run clinical trials of potential neuroprotective agents has been set as a goal of the NIH...
  34. Parkinson's Disease Neuroprotection Clinical Center
    Charles Adler; Fiscal Year: 2005
    ..To this end creating a multi-center study group to run clinical trials of potential neuroprotective agents has been set as a goal of the NIH...
  35. Insecticide Action at the Local Anesthetic Receptor
    DAVID SODERLUND; Fiscal Year: 2009
    ..This research will provide new insight into the structure of the local anesthetic receptor and its role in the neurotoxic actions of PTIs. ..
  36. Insecticide Action at the Local Anesthetic Receptor
    DAVID SODERLUND; Fiscal Year: 2007
    ..This research will provide new insight into the structure of the local anesthetic receptor and its role in the neurotoxic actions of PTIs. [unreadable] [unreadable] [unreadable]..
  37. Insecticide Action at the Local Anesthetic Receptor
    David M Soderlund; Fiscal Year: 2011
    ..This research will provide new insight into the structure of the local anesthetic receptor and its role in the neurotoxic actions of PTIs. ..
  38. Insecticide Action at the Local Anesthetic Receptor
    David M Soderlund; Fiscal Year: 2010
    ..This research will provide new insight into the structure of the local anesthetic receptor and its role in the neurotoxic actions of PTIs. ..
  39. HIGH-THROUGHPUT SCREENING ASSAY FOR NEUROPROTECTIVE AGENTS
    Karima Ferrani Kile; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  40. Combination Drug Therapy in Huntington's Disease
    ROBERT FERRANTE; Fiscal Year: 2007
    ..compounds or their analogs are available for human use and represent the immediate pipeline of candidate neuroprotective agents for clinical trials in HD...
  41. Combination Drug Therapy in Huntington's Disease
    ROBERT FERRANTE; Fiscal Year: 2006
    ..compounds or their analogs are available for human use and represent the immediate pipeline of candidate neuroprotective agents for clinical trials in HD...
  42. Canonical Transient Receptor Potential Channels and Excitotoxicity
    Fang Zheng; Fiscal Year: 2010
    ..However, efforts to develop ionotropic glutamate receptor antagonists as neuroprotective agents have yet to be successful;alternative molecular targets for developing neuroprotective compounds need to ..
  43. Canonical Transient Receptor Potential Channels and Excitotoxicity
    Fang Zheng; Fiscal Year: 2009
    ..However, efforts to develop ionotropic glutamate receptor antagonists as neuroprotective agents have yet to be successful;alternative molecular targets for developing neuroprotective compounds need to ..
  44. Combination Drug Therapy in Huntington's Disease
    ROBERT FERRANTE; Fiscal Year: 2005
    ..compounds or their analogs are available for human use and represent the immediate pipeline of candidate neuroprotective agents for clinical trials in HD...
  45. Combination Drug Therapy in Huntington's Disease
    ROBERT FERRANTE; Fiscal Year: 2004
    ..compounds or their analogs are available for human use and represent the immediate pipeline of candidate neuroprotective agents for clinical trials in HD...
  46. A Novel Neuroprotective Approach for Ischemia
    Zhi Gang Jiang; Fiscal Year: 2007
    ..At the end of the phase II period, we expect to submit an IND application to the FDA to use PAN-811 for the treatment of transient ischemic stroke and initiate phase Ib clinical trials. [unreadable] [unreadable]..
  47. Phase II Trial of Tiopronin in Aneurysmal Subarachnoid Hemorrhage
    Edward Connolly; Fiscal Year: 2009
    ..This would spark further study that could further explore neuroprotective pre-treatment of cerebral ischemia, and thus help neutralize a major source of morbidity and mortality in this disease process. ..
  48. A Novel Neuroprotective Approach for Ischemia
    Zhi Gang Jiang; Fiscal Year: 2006
    ..At the end of the phase II period, we expect to submit an IND application to the FDA to use PAN-811 for the treatment of transient ischemic stroke and initiate phase Ib clinical trials. [unreadable] [unreadable]..
  49. Phase II Trial of Tiopronin in Aneurysmal Subarachnoid Hemorrhage
    EDWARD SANDER CONNOLLY; Fiscal Year: 2010
    ..This would spark further study that could further explore neuroprotective pre-treatment of cerebral ischemia, and thus help neutralize a major source of morbidity and mortality in this disease process. ..
  50. Characterizing Beta Lactams as Neuroprotectants for Amyotrophic Lateral Sclerosis
    Jeffrey Rothstein; Fiscal Year: 2009
    ..These sequential phases will set the stage for future practical translation towards rational clinical trial design. ..
  51. Characterizing Beta Lactams as Neuroprotectants for Amyotrophic Lateral Sclerosis
    Jeffrey D Rothstein; Fiscal Year: 2010
    ..These sequential phases will set the stage for future practical translation towards rational clinical trial design. ..
  52. PARAMEDIC FIELD INITIATION OF MAGNESIUM NEUROPROTECTIVE
    Jeffrey Saver; Fiscal Year: 2001
    ..study will demonstrate the feasibility of performing randomized, controlled clinical trials of promising neuroprotective agents in the field...
  53. PARAMEDIC FIELD INITIATION OF MAGNESIUM NEUROPROTECTIVE
    Jeffrey Saver; Fiscal Year: 2000
    ..study will demonstrate the feasibility of performing randomized, controlled clinical trials of promising neuroprotective agents in the field...
  54. Characterizing Beta Lactams/Neuroprotective Drugs/ALS
    Jeffrey Rothstein; Fiscal Year: 2006
    ..These sequential phases will set the stage for future practical translation towards rational clinical trial design. ..
  55. Characterizing Beta Lactams/Neuroprotective Drugs/ALS
    Jeffrey Rothstein; Fiscal Year: 2005
    ..These sequential phases will set the stage for future practical translation towards rational clinical trial design. ..
  56. PARAMEDIC FIELD INITIATION OF MAGNESIUM NEUROPROTECTIVE
    Jeffrey Saver; Fiscal Year: 2003
    ..study will demonstrate the feasibility of performing randomized, controlled clinical trials of promising neuroprotective agents in the field...
  57. PARAMEDIC FIELD INITIATION OF MAGNESIUM NEUROPROTECTIVE
    Jeffrey Saver; Fiscal Year: 1999
    ..study will demonstrate the feasibility of performing randomized, controlled clinical trials of promising neuroprotective agents in the field...
  58. PARAMEDIC FIELD INITIATION OF MAGNESIUM NEUROPROTECTIVE
    Jeffrey Saver; Fiscal Year: 2002
    ..study will demonstrate the feasibility of performing randomized, controlled clinical trials of promising neuroprotective agents in the field...
  59. Neuroprotective and Antiviral Effects of BMD-101 and BMD-104 in HIV Infection
    Joseph P Steiner; Fiscal Year: 2010
    ..Based on these premises, we developed a novel neurotoxicity assay for neuroprotective agents which utilizes rat and human primary neuronal cultures...
  60. Peptidic Ligands for Kappa Opioid Receptors
    JANE ALDRICH; Fiscal Year: 2007
    ..Kappa receptor ligands also have a number of other potential therapeutic applications, including as neuroprotective agents and potentially in the treatment of AIDS...
  61. ASCORBATE AND GLUTATHIONE IN CNS INJURY
    Margaret Rice; Fiscal Year: 2000
    Cerebral antioxidants are neuroprotective agents that prevent oxidative injury during normal aerobic metabolism. Ascorbic acid (ascorbate) and glutathione (GSH) are the most abundant antioxidants of low molecular weight in the CNS...
  62. PHARMACOLOGICAL NEUROPROTECTION IN GLAUCOMA
    Arthur Neufeld; Fiscal Year: 2001
    ..of this work is the identification of a class of compounds that could be developed as a pharmacological neuroprotective agents for the treatment of patients with glaucomatous optic neuropathy...
  63. ASCORBATE AND GLUTATHIONE IN CNS INJURY
    Margaret Rice; Fiscal Year: 1999
    Cerebral antioxidants are neuroprotective agents that prevent oxidative injury during normal aerobic metabolism. Ascorbic acid (ascorbate) and glutathione (GSH) are the most abundant antioxidants of low molecular weight in the CNS...
  64. PHARMACOLOGICAL NEUROPROTECTION IN GLAUCOMA
    Arthur Neufeld; Fiscal Year: 1999
    ..of this work is the identification of a class of compounds that could be developed as a pharmacological neuroprotective agents for the treatment of patients with glaucomatous optic neuropathy...
  65. A HIGH-THROUGHPUT SCREEN FOR ANTI-NECROTIC COMPOUNDS
    DONALD KIRSCH; Fiscal Year: 2006
    ..2) Execute a pilot screen of -3000 highly selected compounds to identify neuroprotective agents. A library of known bioactive compounds, including many currently marketed drugs, will be screened for ..
  66. PHARMACOLOGICAL NEUROPROTECTION IN GLAUCOMA
    Arthur Neufeld; Fiscal Year: 2000
    ..of this work is the identification of a class of compounds that could be developed as a pharmacological neuroprotective agents for the treatment of patients with glaucomatous optic neuropathy...
  67. Novel visual outcome measures in optic neuritis and multiple sclerosis
    Laura Balcer; Fiscal Year: 2007
    ..as new visual outcomes for clinical trials in MS, and in acute ON as a model system for future testing of neuroprotective agents. Specific Aim 2: Determine how new visual outcomes, low-contrast letter acuity and OCT, reflect vision-..
  68. PARKINSON DISEASE NEUROPROTECTION CLINICAL TRIAL CENTER
    Bala Manyam; Fiscal Year: 2003
    ..abstract_text> ..
  69. Novel visual outcome measures in optic neuritis and multiple sclerosis
    Laura Balcer; Fiscal Year: 2009
    ..as new visual outcomes for clinical trials in MS, and in acute ON as a model system for future testing of neuroprotective agents. Specific Aim 2: Determine how new visual outcomes, low-contrast letter acuity and OCT, reflect vision-..
  70. PARKINSON DISEASE NEUROPROTECTION CLINICAL TRIAL CENTER
    Bala Manyam; Fiscal Year: 2005
    ..abstract_text> ..
  71. Novel visual outcome measures in optic neuritis and multiple sclerosis
    Laura Balcer; Fiscal Year: 2010
    ..as new visual outcomes for clinical trials in MS, and in acute ON as a model system for future testing of neuroprotective agents. Specific Aim 2: Determine how new visual outcomes, low-contrast letter acuity and OCT, reflect vision-..
  72. PARKINSON DISEASE NEUROPROTECTION CLINICAL TRIAL CENTER
    Bala Manyam; Fiscal Year: 2002
    ..abstract_text> ..
  73. Novel Clinical and Ocular Imaging Outcomes with Long-Term Follow-Up in MS
    Laura Balcer; Fiscal Year: 2010
    ..in MS clinical trials, particularly for the anticipated next generation of trials that will involve neuroprotective agents. While our cross-sectional, preliminary longitudinal, and clinical trial data represent a significant step ..
  74. Novel Clinical and Ocular Imaging Outcomes with Long-Term Follow-Up in MS
    Laura Balcer; Fiscal Year: 2009
    ..in MS clinical trials, particularly for the anticipated next generation of trials that will involve neuroprotective agents. While our cross-sectional, preliminary longitudinal, and clinical trial data represent a significant step ..
  75. BLOOD/BRAIN BARRIER DRUG DELIVERY OF BDNF IN ISCHEMIA
    William Pardridge; Fiscal Year: 2001
    Neurotrophins, such as brain-derived neurotrophic factor (BDNF), are potential neuroprotective agents for the treatment of stroke, trauma, and neurodegenerative diseases...
  76. BLOOD/BRAIN BARRIER DRUG DELIVERY OF BDNF IN ISCHEMIA
    William Pardridge; Fiscal Year: 2000
    Neurotrophins, such as brain-derived neurotrophic factor (BDNF), are potential neuroprotective agents for the treatment of stroke, trauma, and neurodegenerative diseases...
  77. BLOOD/BRAIN BARRIER DRUG DELIVERY OF BDNF IN ISCHEMIA
    William Pardridge; Fiscal Year: 1999
    Neurotrophins, such as brain-derived neurotrophic factor (BDNF), are potential neuroprotective agents for the treatment of stroke, trauma, and neurodegenerative diseases...
  78. BLOOD/BRAIN BARRIER DRUG DELIVERY OF BDNF IN ISCHEMIA
    William Pardridge; Fiscal Year: 2001
    Neurotrophins, such as brain-derived neurotrophic factor (BDNF), are potential neuroprotective agents for the treatment of stroke, trauma, and neurodegenerative diseases...
  79. BLOOD/BRAIN BARRIER DRUG DELIVERY OF BDNF IN ISCHEMIA
    William Pardridge; Fiscal Year: 2002
    Neurotrophins, such as brain-derived neurotrophic factor (BDNF), are potential neuroprotective agents for the treatment of stroke, trauma, and neurodegenerative diseases...
  80. Neurotrophin Blood/Brain Barrier Delivery in Ischemia
    William Pardridge; Fiscal Year: 2004
    Neurotrophins are powerful neuroprotective agents in global or regional brain ischemia when the protein is injected directly into the ischemic brain...
  81. Neurotrophin Blood/Brain Barrier Delivery in Ischemia
    William Pardridge; Fiscal Year: 2003
    Neurotrophins are powerful neuroprotective agents in global or regional brain ischemia when the protein is injected directly into the ischemic brain...
  82. Neurotrophin Blood/Brain Barrier Delivery in Ischemia
    William Pardridge; Fiscal Year: 2006
    unreadable] DESCRIPTION (provided by applicant): Neurotrophins are powerful neuroprotective agents in global or regional brain ischemia when the protein is injected directly into the ischemic brain...
  83. Neurotrophin Blood/Brain Barrier Delivery in Ischemia
    William Pardridge; Fiscal Year: 2005
    Neurotrophins are powerful neuroprotective agents in global or regional brain ischemia when the protein is injected directly into the ischemic brain...
  84. Novel Adjunctive Therapies for NeuroAIDS
    Harris A Gelbard; Fiscal Year: 2010
    ..At the end of this project period, the group will apply to the NIH RAID program for support in scaling up the synthesis, manufacture and safety testing of this drug for investigational new drug (IND) filing with the FDA. ..
  85. Endogenous neuroprotective agents in Parkinson's disease
    Amanda Smith; Fiscal Year: 2006
    ..The mentors that are described herein will actively participate in this undertaking and will further mediate increasing the network of neuroscientists in which I interact locally and nationally. ..
  86. Endogenous neuroprotective agents in Parkinson's disease
    Amanda Smith; Fiscal Year: 2005
    ..The mentors that are described herein will actively participate in this undertaking and will further mediate increasing the network of neuroscientists in which I interact locally and nationally. ..
  87. Endogenous neuroprotective agents in Parkinson's disease
    Amanda Smith; Fiscal Year: 2004
    ..The mentors that are described herein will actively participate in this undertaking and will further mediate increasing the network of neuroscientists in which I interact locally and nationally. ..
  88. Endogenous neuroprotective agents in Parkinson's disease
    Amanda Smith; Fiscal Year: 2007
    ..The mentors that are described herein will actively participate in this undertaking and will further mediate increasing the network of neuroscientists in which I interact locally and nationally. ..